Table 1 Main trials with monoclonal antibodies associated with radiotherapy in locally advanced SCCHN

Bonner et al. [6, 21]

RT

5-yr 36.4%

18%

52%

RT + cetuximab

5-yr 45.6%

23%

56%

Fury MG et al. [17]

cet + bevacizumab + CDDP + RT

2-yr 88.5%

2-yr 92.8%

3%

3%

Lefebvre JL et al. [22]

TPF → RT + CDDP vs

92%

26%

43%

TPF → RT + cet

89%

57%

43%

Mesia R et al. [25]

RT + cet vs

1-yr 47%

2%

RT + cet + 12 weeks maint

1-yr 59%

7%

2-yr similar

Egloff AM et al. [47]

Cet + CDDP +

2-yr 47%

2-yr 66%

66.7%

26%

55%

46%

RT + cet maint

Ang KK et al. [26]

RT + CDDP vs

3-yr 61.2%

3-yr 72.9%

33%

RT + CDDP + cet

3-yr 58.9%

3-yr 75.8%

43%

Mesia R et al. [28]

RT + CDDP vs

2-yr 68%

24%

27%

RT + CDDP + PMab

2-yr 61%

55%

40%

Giralt J et al. [29]

RT + PMab vs

2-yr 51%

40%

42%

RT + CDDP

2-yr 61%

32%

40%

Siu LL et al. [30]

RT + CDDP vs

2-yr 73%

2-yr 85%

RT + Pmab

2-yr 76%

2-yr 88%

Reddy BK et al. [31]

RT + CDDP + NMab

5-yr 57%

11%

4%

CDDP + RT

5-yr 26%

5%

1%

RT + NMab

5-yr 39%

10%

2%

RT

5-yr 26%

16%

Eriksen JG et al. [33]

RT+ CDDP + nimo + ZMab

4-yr 71%

29%

Vs RT + CDDP + nimo

4-yr 73%